Navigation Links
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Date:4/26/2009

thout limitation, statements regarding the timing, progress and results of the clinical development, safety, regulatory processes, and commercialization efforts of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
4. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
7. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
8. Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
9. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
10. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015  Research ... addition of the "An Introduction to the ... 2015)" conference to their offering. ... the European medical device legislation. It will explain ... involvement of Notified Bodies, how to choose one ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has ... Legislation (London, UK - November 16-17, 2015)" conference ... EU modules concerning Pharmacovigilance are a major departure in ... Europe . The intention of the course ... examine how they overlap and fit together and what ...
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... Companies" to their offering. This ... clinical specialty, aimed at improving patient care by ... adjust the dose of drugs for improving outcome. ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2
... 2011 Amarin Corporation plc (Nasdaq: AMRN ... cardiovascular disease, today announced that Executive Chairman and Chief ... EDT on April, 6, 2011 at the 10th Annual ... President, John Thero, will be available at the conference ...
... VIVUS, Inc. (Nasdaq: VVUS ) today announced that ... in a poster presentation at the 60th Annual Scientific Meeting ... 2011 in New Orleans, Louisiana. Following are details ... presented in Hall F of The Ernest N. Morial Convention ...
Cached Medicine Technology:Amarin to Present at the 10th Annual Needham Healthcare Conference 2Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting 2
(Date:9/3/2015)... ... September 03, 2015 , ... Hunters Creek Retrievers is again ... champion AKC Black Lab Puppy. Celebrate Fall 2015 with unlimited Free Hugs and K9 ... to enjoy Thanksgiving and Christmas with an extra big smile. , This adorable ...
(Date:9/3/2015)... ... 03, 2015 , ... AvePoint, the established leader in enabling enterprise ... 4 – AvePoint’s solution for facilitating two-way collaboration and external sharing without ever ... This is the fifth consecutive year an AvePoint product has made the list. ...
(Date:9/3/2015)... WI (PRWEB) , ... September 03, 2015 , ... At ... after becoming dissatisfied with the traditional health care model, where the primary care physician ... of individuals who want to become educated about their health issues and empowered to ...
(Date:9/3/2015)... ... 03, 2015 , ... Leading post-acute electronic medical record (EMR) ... joining the company’s executive leadership team as VP of Product and as VP ... healthcare product and project management. He has been with HealthWyse since 2000 in ...
(Date:9/2/2015)... (PRWEB) , ... September 03, 2015 , ... ... Group and frequently listed among the most influential leaders in healthcare, will offer ... Delivery Coalition, to take place October 15-16, 2015, in Palm Harbor, Florida, at ...
Breaking Medicine News(10 mins):Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3
... to reduce risk , , SUNDAY, Jan. 27 (HealthDay News) ... homes through foundation cracks, causes 100 times more deaths ... Agency. , To heighten awareness of that potential danger, ... Month. , Radon is the second leading cause of ...
... particular family of diseases are passed down from mother to ... the disease differing widely. The research, funded by the Wellcome ... risk of developing a mitochondrial disease which can cause muscle ... and animal cells contain many mitochondria, which are involved in ...
... ROLLING MEADOWS, Ill., Jan. 26 The American,Society ... of leaders in the field of cosmetic and ... filed by Public Citizen with the,U.S. Food and ... supports the current labeling of all Botox(R) products,for ...
... CHICAGO, Jan. 25 Continuing its efforts to,educate, ... PATIENT, a,not-for-profit patient-focused organization, is hosting its 25-minute live,call-in ... air on Monday, January 28, at 6:00 PM on ... discussion on how to make the,most out of your ...
... Better Enjoy Her Time with,Friends and Family, SACRAMENTO, ... moved into a senior citizen center to enjoy the ... made it,increasingly difficult for her to go to the ... a power wheelchair donated by The SCOOTER Store,Mrs. Pittman ...
... WellPoint, Inc. (NYSE:,WLP) announced today that senior management ... on January 30, 2008. The presentation is,expected to ... All interested parties are invited to listen to ... and selecting the "Investor,Info" link. Following the ...
Cached Medicine News:Health News:Radon Gas More Deadly Than Carbon Monoxide Poisoning 2Health News:Mitochondrial 'bottleneck' cracked 2Health News:American Society for Dermatologic Surgery Supports Current Labeling of Allergan's Botox(R) Products 2Health News:Making the Most Out of Your Doctor's Visit 2Health News:Disabled Sacramento Woman, 110, Receives Power Wheelchair Donation from The SCOOTER Store 2Health News:WellPoint Announces Appearance at Upcoming Conference 2
XL Cervical Curette comes with a bayonet design and satin black handles having instrument length 9.5" (24 cm), working distance4.1" (10.4 cm) and handle width 0.6" (1.5 cm)....
Bone Curette, 170 mm...
Bone Curette, 145 mm...
Endocrette Endocervical Curette is a stainless-steel curette with closed blade....
Medicine Products: